Insider Transactions Reported by 28 Insiders of Avalo Therapeutics, Inc.

Symbol
AVTX on Nasdaq
Location
Wayne, PA

Insiders trading volume in the past year

Avalo Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
GARRY A. NEIL Chief Executive Officer $2,085,333 28 Mar 2025
Christopher Sullivan Chief Financial Officer $480,549 10 Dec 2025
ARMISTICE CAPITAL, LLC 10%+ Owner $397,771 26 Jun 2023
June Sherie Almenoff Director $88,830 17 Jun 2025
Samantha Truex Director $80,370 17 Jun 2025
AARON KANTOFF Director $80,370 17 Jun 2025
GILLA KAPLAN Director $80,370 17 Jun 2025
Mitchell Chan Director $80,370 17 Jun 2025
Jonathan Goldman Director $53,577 -$162,937 -75% 14 Nov 2025
James Archie Harrell Jr Chief Commercial Officer $19,096 10 Dec 2021
H. Jeffrey Wilkins Chief Medical Officer $17,334 10 Dec 2021
Rita Jain Director $15,373 31 Dec 2025
PAUL VARKI Chief Legal Officer $14,899 10 Dec 2025
Mittie Doyle Chief Medical Officer $14,850 10 Dec 2025
Kevin Robert Lind Director $12,499 31 Dec 2025
Jennifer Riley Chief Strategy Officer $10,885 10 Dec 2025
Schond Greenway Cfo $2,017 10 Dec 2021
Taylor Boyd Chief Business Officer 01 Oct 2025
Stephen Smolinski Chief Commercial Officer 04 Jan 2022
Magnus Persson Director 20 Dec 2023
Joseph M. Miller Director 31 Mar 2022
Caissa Capital Management ltd. 10%+ Owner 26 Jun 2023
MICHAEL F. COLA Chief Executive Officer, Director 01 Oct 2021
Phil Gutry Director 01 Dec 2021
Illya Keith Maher Director 15 Oct 2021
Suzanne Louise Bruhn Director 10 Nov 2021
Michael Thomas Heffernan Director 17 Jun 2025
SOL J. BARER Director 15 Jun 2021

Recent Insider Transactions by Companies or Individuals for Avalo Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.